ArticleOncotarget2016

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer.

Abderrahim El Guerrab et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.